Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study.
Narciso P, Bucciardini R, Tozzi V, Bellagamba R, Ivanovic J, Giulianelli M, Scevola S, Palummieri A, Fragola V, Massella M, Fracasso L, De Vita R, Pierro P, Del Maestro A, Mirra M, Weimer L. Narciso P, et al. Among authors: weimer l. AIDS Res Hum Retroviruses. 2009 Oct;25(10):979-87. doi: 10.1089/aid.2009.0029. AIDS Res Hum Retroviruses. 2009. PMID: 19795984 Clinical Trial.
Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
Pirillo M, Palmisano L, Pellegrini M, Galluzzo C, Weimer L, Bucciardini R, Fragola V, Andreotti M, Marchei E, Pichini S, Vella S, Giuliano M. Pirillo M, et al. Among authors: weimer l. AIDS Res Hum Retroviruses. 2010 May;26(5):541-5. doi: 10.1089/aid.2009.0116. AIDS Res Hum Retroviruses. 2010. PMID: 20455761 Clinical Trial.
Relationship between health-related quality of life measures and high HIV viral load in HIV-infected triple-class-experienced patients.
Bucciardini R, Pugliese K, Weimer L, Digregorio M, Fragola V, Mancini M, Maroccia Z, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Guaraldi G, Cirioni O, Ortu F, Parruti G, Mannazzu M, Libertone R, Donnini S, Floridia M; ISS-NIA Study Group. Bucciardini R, et al. Among authors: weimer l. HIV Clin Trials. 2014 Jul-Aug;15(4):176-83. doi: 10.1310/hct1504-176. HIV Clin Trials. 2014. PMID: 25143026
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.
Baroncelli S, Pirillo MF, Galluzzo CM, Antoni AD, Ladisa N, Francisci D, d'Ettorre G, Segala D, Vivarelli A, Sozio F, Cirioni O, Weimer LE, Fragola V, Parruti G, Floridia M. Baroncelli S, et al. AIDS Res Hum Retroviruses. 2015 Jan;31(1):71-7. doi: 10.1089/AID.2014.0060. AIDS Res Hum Retroviruses. 2015. PMID: 25092266 Free PMC article.
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group. Weimer LE, et al. J Antimicrob Chemother. 2013 Jan;68(1):193-9. doi: 10.1093/jac/dks341. Epub 2012 Sep 14. J Antimicrob Chemother. 2013. PMID: 22984206 Free PMC article.
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.
Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte Ad, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers. Palmisano L, et al. Among authors: weimer le. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):39-47. J Acquir Immune Defic Syndr. 2007. PMID: 17972364 Clinical Trial.
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, Mercuri A, Cavalli A, Fragola V, Monno L, Degli Antoni A, Ladisa N, Francisci D, Bucciardini R, Floridia M. Baroncelli S, et al. Among authors: weimer le. J Antimicrob Chemother. 2012 Jun;67(6):1479-85. doi: 10.1093/jac/dks055. Epub 2012 Feb 23. J Antimicrob Chemother. 2012. PMID: 22361986 Free PMC article.
HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.
Michelini Z, Galluzzo CM, Pirillo MF, Francisci D, Degli Antoni A, Vivarelli A, Ladisa N, Cirioni O, Weimer LE, Fragola V, Cara A, Floridia M, Baroncelli S. Michelini Z, et al. J Med Virol. 2016 Dec;88(12):2115-2124. doi: 10.1002/jmv.24581. Epub 2016 May 30. J Med Virol. 2016. PMID: 27197719
No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir.
Baroncelli S, Mezzaroma I, Fantauzzi A, Galluzzo CM, Antoni AD, Vullo V, Francisci D, Ladisa N, Vivarelli A, Cirioni O, Sighinolfi L, Weimer LE, Fragola V, Fidanza R, Cara A, Palmisano L. Baroncelli S, et al. Among authors: weimer le. Antivir Ther. 2013;18(3):321-7. doi: 10.3851/IMP2433. Epub 2012 Oct 9. Antivir Ther. 2013. PMID: 23047152
114 results